J. Kuby, T. Kindt, O. B. Goldsby, and R. Kuby-immunology, , 2006.

M. Sadelain, R. Brentjens, and I. Riviere, The basic principles of chimeric antigen receptor (CAR) design. Cancer Discov, avr, vol.3, issue.4, pp.388-98, 2013.

Z. L. Chang and Y. Y. Chen, CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond, Trends Mol Med. mai, vol.23, issue.5, pp.430-50, 2017.

M. V. Maus and B. L. Levine, Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist, The Oncologist. mai, vol.21, issue.5, pp.608-625, 2016.

G. Dotti, S. Gottschalk, B. Savoldo, and M. K. Brenner, Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells, Disponible sur, vol.257, 2014.

Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci, vol.90, issue.2, pp.720-724, 1993.

J. H. Esensten, Y. A. Helou, G. Chopra, A. Weiss, and J. A. Bluestone, CD28 costimulation: from mechanism to therapy, Immunity. 17 mai, vol.44, issue.5, pp.973-88, 2016.

Y. Kuwana, Y. Asakura, N. Utsunomiya, M. Nakanishi, Y. Arata et al., Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptorderived C regions, Biochem Biophys Res Commun. 31 déc, vol.149, issue.3, pp.960-968, 1987.

H. Li and Y. Zhao, Increasing the safety and efficacy of chimeric antigen receptor T cell therapy, Protein Cell. août, vol.8, issue.8, pp.573-89, 2017.

M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar et al., A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.12, issue.20, pp.6106-6121, 2006.

B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood et al., Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood. 15 sept, vol.112, issue.6, pp.2261-71, 2008.

J. Maher, R. J. Brentjens, G. Gunset, I. Rivière, and M. Sadelain, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR? /CD28 receptor, Nat Biotechnol. janv, vol.20, issue.1, pp.70-75, 2002.

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia, N Engl J Med. 25 août, vol.365, issue.8, pp.725-758, 2011.

M. Chmielewski and H. Abken, TRUCKs: the fourth generation of CARs, Expert Opin Biol Ther, vol.15, issue.8, pp.1145-54, 2015.

X. Wang and I. Rivière, Clinical manufacturing of CAR T cells: foundation of a promising therapy, Mol Ther Oncolytics, vol.3, p.16015, 2016.

R. Iu--td and . Orphanet,

D. Sur,

J. Liu, J. F. Zhong, X. Zhang, and C. Zhang, Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies, J Hematol OncolJ Hematol Oncol. 31 janv, vol.10, issue.1, p.35, 2017.

, Universal Chimeric Antigen Receptors | Cellectis

R. Benjamin, Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia, p.17

H. J. Jackson, S. Rafiq, and R. J. Brentjens, Driving CAR T-cells forward, Nat Rev Clin Oncol. juin, vol.13, issue.6, pp.370-83, 2016.

K. J. Savage, Primary Mediastinal Large B-Cell Lymphoma. The Oncologist. 5 janv, vol.11, issue.5, pp.488-95, 2006.

A. Belot, M. Velten, P. Grosclaude, N. Bossard, G. Launoy et al., Estimation nationale de l'incidence et de la mortalité par cancer en France entre, p.136, 1980.

A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence des cancers en France entre 1980 et 2012 / 2013 / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil, vol.88, 2013.

, HAS. Avis de la CT du 12 décembre 2018 -KYMRIAH (tisagenlecleucel), CAR T anti-CD19 (LDGCB)

, HAS. Avis de la CT du 05 décembre 2018 -YESCARTA (axicabtagene ciloleucel), CAR T anti-CD19

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

C. Bonnet, B. D. Prijck, and M. Lejeune, Prise en charge du lymphome B diffus à grandes cellules en 2012, Rev Médicale Suisse, vol.9, 2012.

H. Tilly, M. Gomes-da-silva, U. Vitolo, A. Jack, M. Meignan et al., Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 1 sept, vol.26, issue.suppl_5, pp.116-141, 2015.

J. Rovira, A. Valera, L. Colomo, X. Setoain, S. Rodríguez et al., Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy, Ann Hematol, vol.94, issue.5, pp.803-815, 2015.

J. S. Abramson, M. L. Palomba, L. I. Gordon, M. A. Lunning, J. E. Arnason et al., High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort, Blood. 7 déc, vol.130, issue.1, pp.581-581, 2017.

S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos et al., Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med. 28 déc, vol.377, issue.26, pp.2531-2575, 2017.

J. S. Abramson, . Updated, . Long, . Clinical, P. In-transcend-nhl-001 et al., R/R AGGRESSIVE NHL, 2018.

G. Salles, P. Sesques, E. Ferrant, V. Safar, H. Ghesquieres et al., L'émergence des traitements par cellules CAR-T dans les lymphomes, Bull Cancer (Paris). 1 déc, vol.105, pp.168-77, 2018.

, Updated Analysis of JULIET Trial: Tisagenlecleucel in Relapsed or Refractory DLBCL -The ASCO Post, 2018.

S. J. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann et al., Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Blood. 7 déc, vol.130, issue.1, pp.577-577, 2017.

, Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of lisocel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO

, HAS. Avis de la CT du 12 décembre 2018 -KYMRIAH (tisagenlecleucel), CAR T anti-CD19 (LAL)

S. L. Cooper and P. A. Brown, Treatment of Pediatric Acute Lymphoblastic Leukemia, Pediatr Clin North Am. févr, vol.62, issue.1, pp.61-73, 2015.

M. J. Hossain, L. Xie, and S. M. Mccahan, Characterization of Pediatric Acute Lymphoblastic Leukemia Survival Patterns by Age at Diagnosis, J Cancer Epidemiol, 2014.

R. Iu--td and . Orphanet, Leucémie lymphoblastique aiguë

D. Sur,

F. Huguet, T. Leguay, E. Raffoux, X. Thomas, K. Beldjord et al., Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study, J Clin Oncol. 5 janv, vol.27, issue.6, pp.911-919, 2009.

, Pronostic et survie pour la leucémie aiguë lymphoblastique -Société c

N. Gökbuget, H. Dombret, J. Ribera, A. K. Fielding, A. Advani et al., International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia, Haematologica. 1 sept, 2016.

D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J. M. Ribera et al., Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 7 avr, p.25, 2016.

D. Lara and M. Gauthier, Acute lymphocytic leukemia, Hématologie. 1 mars, vol.20, issue.2, pp.116-145, 2014.

N. L. Seibel, P. G. Steinherz, H. N. Sather, J. B. Nachman, C. Delaat et al., Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group, Blood. 1 mars, vol.111, issue.5, pp.2548-55, 2008.

S. L. Maude, T. W. Laetsch, J. Buechner, S. Rives, M. Boyer et al., Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med. 1 févr, vol.378, issue.5, pp.439-487, 2018.

I. Rahal, A. Cabannes-hamy, and N. Boissel, Traitement par CAR-T des leucémies aiguës de l'adulte, Bull Cancer (Paris). 1 déc, vol.105, pp.158-67, 2018.

D. W. Lee, J. N. Kochenderfer, M. Stetler-stevenson, Y. K. Cui, C. Delbrook et al., T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet Lond Engl. 7 févr, vol.385, issue.9967, pp.517-545, 2015.

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

. Anti-cd19, White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma -Full Text View -ClinicalTrials.gov

C. J. Turtle, L. Hanafi, C. Berger, T. A. Gooley, S. Cherian et al., CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest. 25 avr, vol.126, issue.6, pp.2123-2161, 2016.

, Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia -Full Text View -ClinicalTrials

W. Qasim, H. Zhan, S. Samarasinghe, S. Adams, P. Amrolia et al., Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci Transl Med. 25 janv, vol.9, issue.374, p.2013, 2017.

, Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia -Full Text View -ClinicalTrials.gov [Internet

, Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia -Full Text View -ClinicalTrials.gov

R. A. Gardner, O. Finney, C. Annesley, H. Brakke, C. Summers et al., Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood. 22 juin, vol.129, issue.25, pp.3322-3353, 2017.

, A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia -Full Text View -ClinicalTrials.gov

J. H. Park, I. Rivière, M. Gonen, X. Wang, B. Sénéchal et al., Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia, N Engl J Med, vol.31, 2018.

D. Sur,

, Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 -Full Text View -ClinicalTrials.gov

D. Sur,

K. A. Hay, J. Gauthier, A. V. Hirayama, J. M. Voutsinas, Q. Wu et al., Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells, Blood. 1 janv, 2019.

, Putting a number on CAR-T deaths

D. Sur,

, Juno: we could have saved JCAR015

D. Sur,

M. Y. Kim, K. Yu, S. S. Kenderian, R. M. Chen, S. Shin et al., Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia, Cell. 31 mai, vol.173, issue.6, pp.1439-1453, 2018.

S. Gill, Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells

D. Sur,

T. Leguay, Adera meeting, Les CAR T anti CD123 dans les leucémies aiguës myéloblastiques et les leucémies aiguës à cellules dendritiques, 2019.

H. Jetani, I. Garcia-cadenas, T. Nerreter, S. Thomas, J. Rydzek et al., CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib, Leukemia, vol.32, issue.5, pp.1168-79, 2018.

. Sfh and . Hématologie,

I. Has and A. Guide, Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique Myélome multiple

M. Ifm-coordonné-par-philippe, . Le-myélome-multiple, . John-libbey, and . Eurotext, , 2009.

S. Gérard, Hématologie clinique et biologique. Arnette, vol.578, 2006.

-. Infocancer, Cancers du sang -Hémopathies -Myélome Multiple (MM) -Maladie -Avant propos

, Le myélome multiple : points clés -Comprendre le myélome multiple

D. Sur,

R. S. Hillman, K. A. Ault, and H. M. Rinder, Hématologie en pratique clinique Guide de diagnostic et de traitement. Médecine-Sciences Flammarion, LAVOISIER MSP, 2007.

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

A. Coppola, A. Tufano, M. D. Capua, and M. Franchini, Bleeding and Thrombosis in Multiple Myeloma and Related Plasma Cell Disorders, Semin Thromb Hemost, vol.37, issue.8, pp.929-974, 2011.

A. Palumbo, H. Avet-loiseau, S. Oliva, H. M. Lokhorst, H. Goldschmidt et al., Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J Clin Oncol, vol.33, issue.26, pp.2863-2872, 2015.

P. R. Greipp, S. Miguel, J. Durie, B. Crowley, J. J. Barlogie et al., International staging system for multiple myeloma, J Clin Oncol Off J Am Soc Clin Oncol. 20 mai, vol.23, issue.15, pp.3412-3432, 2005.

. Sfh, Fiche information patient -Myélome multiple, 2009.

M. Cavo, S. V. Rajkumar, A. Palumbo, P. Moreau, R. Orlowski et al., International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation, Blood. 9 juin, vol.117, issue.23, pp.6063-73, 2011.

H. Ludwig, B. Durie, P. Mccarthy, A. Palumbo, S. Miguel et al., IMWG consensus on maintenance therapy in multiple myeloma, Blood. 29 mars, vol.119, issue.13, pp.3003-3018, 2012.

A. Palumbo, S. V. Rajkumar, S. Miguel, J. F. Larocca, A. Niesvizky et al., International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation, J Clin Oncol Off J Am Soc Clin Oncol. 20 févr, vol.32, issue.6, pp.587-600, 2014.

. Sfh and . Referentiel, , pp.99-105, 2008.

E. Velcade,

D. Sur,

E. Thalidomide,

E. Revlimid,

E. Ninlaro,

D. Sur,

E. Kyprolis,

E. Imnovid,

D. Sur,

E. Farydak,

D. Sur,

E. Empliciti,

E. Darzalex,

A. Rcp-alkeran,

D. Sur,

, CAR T Cell Therapy in Heavily Pretreated Patients With Myeloma -The ASCO Post

, Study of bb2121 in Multiple Myeloma -Full Text View -ClinicalTrials.gov [Internet

, Meeting Library | bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study

D. Sur,

, Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

. Bluebird-bio and . Inc, Disponible sur

, LEGEND-2 trial: phase I results using LCAR-B38M CAR-T therapy for patients with relapsed refractory multiple myeloma

W. Zhao, J. Liu, B. Wang, Y. Chen, X. Cao et al., A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma, J Hematol OncolJ Hematol Oncol. 20 déc, vol.11, issue.1, p.141, 2018.

, LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma -Full Text View -ClinicalTrials.gov [Internet

, CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma -Full Text View -ClinicalTrials, A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell

D. Sur,

C. Hulin, Les CAR T dans le myélome multiple

N. Shah, M. Alsina, D. S. Siegel, S. Jagannath, D. Madduri et al., Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy, Blood, vol.132, issue.1, pp.488-488, 2018.

, Study of bb21217 in Multiple Myeloma -Full Text View -ClinicalTrials.gov

S. Mailankody, M. Htut, K. P. Lee, W. Bensinger, T. Devries et al., Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE), Blood, vol.132, issue.1, pp.957-957, 2018.

, Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma -Full Text View -ClinicalTrials.gov

T. Gregory, A. D. Cohen, C. L. Costello, S. A. Ali, J. G. Berdeja et al., Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM), Blood, vol.132, issue.1, pp.1012-1012, 2018.

P. , 101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) -Full Text View -ClinicalTrials.gov

S. Jiang, J. J. Hao, S. Yang, M. Chen, L. Ruan et al., Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma, Blood, vol.132, issue.1, pp.960-960, 2018.

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

, CARsgen Therapeutics' IND for CT053 Receives Clearance in China

D. Sur,

, Hrain Receives Another Clinical Trial Approval in Multiple Myeloma, Leading Chin -Hrain News -??????????????

, BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma -Full Text View -ClinicalTrials.gov [Internet

Y. Liu, Z. Chen, H. Fang, R. Wei, K. Yu et al., Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma, Blood, vol.132, issue.1, pp.956-956, 2018.

, Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT -Full Text View -ClinicalTrials.gov

X. Shi, L. Yan, J. Shang, S. Qu, L. Kang et al., Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study, Blood, vol.132, issue.1, pp.1009-1009, 2018.

, Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies -The ASCO Post

L. A. Johnson, J. Scholler, T. Ohkuri, A. Kosaka, P. R. Patel et al., Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma, Sci Transl Med. 18 févr, vol.7, issue.275, pp.275-297, 2015.

S. Yu, A. Li, Q. Liu, T. Li, X. Yuan et al., Chimeric antigen receptor T cells: a novel therapy for solid tumors, J Hematol OncolJ Hematol Oncol, vol.29, issue.1, p.78, 2017.

K. Feng, Y. Guo, H. Dai, Y. Wang, X. Li et al., Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer, Sci China Life Sci. mai, vol.59, issue.5, pp.468-79, 2016.

Y. Zhao, Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng et al., A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity, J Immunol Baltim Md, vol.183, issue.9, pp.5563-74, 1950.

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot et al., Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2, Mol Ther. avr, vol.18, issue.4, pp.843-51, 2010.

G. L. Beatty, A. R. Haas, M. V. Maus, D. A. Torigian, M. C. Soulen et al., Mesothelinspecific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res. févr, vol.2, issue.2, pp.112-132, 2014.

K. Newick, E. Moon, and S. M. Albelda, Chimeric antigen receptor T-cell therapy for solid tumors, Mol Ther Oncolytics. 13 avr, vol.3, p.16006, 2016.

H. Zhang, Z. Ye, Z. Yuan, Z. Luo, and H. Jin, New Strategies for the Treatment of Solid Tumors with CAR-T Cells, Int J Biol Sci. 28 avr, vol.12, issue.6, pp.718-747, 2016.

C. Y. Slaney, M. H. Kershaw, and P. K. Darcy, Trafficking of T cells into tumors, Cancer Res. 15 déc, vol.74, issue.24, pp.7168-74, 2014.

N. Nishio, I. Diaconu, H. Liu, V. Cerullo, I. Caruana et al., Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors, Cancer Res. 15 sept, vol.74, issue.18, pp.5195-205, 2014.

L. Gou, J. Gao, H. Yang, and C. Gao, The landscape of CAR T-cell therapy in the United States and China: A comparative analysis, Int J Cancer. 15 avr, vol.144, issue.8, pp.2043-50, 2019.

, Disponible sur

L. Jérôme and C. Christian, Prise en charge des cellules CAR-T au sein des établissements de santé français : fabrication, distribution, et aspects réglementaires, 2018.

, ANSM. Les médicaments de thérapie innovante (MTI, ATMP) -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

, Haut Conseil des biotechnologies. Manuel du HCB pour l'utilisation confinée d'organismes génétiquement modifiés

, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019

, Déclaration d'utilisation ou demande d'agrément d'utilisation d'O.G.M. en milieu confiné à des fins de recherche, de développement et d'enseignement

, Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation

M. Pinturaud, M. Vasseur, and P. Odou, Rôle du pharmacien hospitalier dans le circuit d'une catégorie de Médicament de Thérapie Innovante : les lymphocytes T exprimant un Récepteur Chimérique à l'Antigène, Bull Cancer (Paris). 1 déc, vol.105, pp.205-218, 2018.

C. L. Bonifant, H. J. Jackson, R. J. Brentjens, and K. J. Curran, Toxicity and management in CAR Tcell therapy, Mol Ther Oncolytics, vol.3, p.16011, 2016.

M. Sharpe and N. Mount, Genetically modified T cells in cancer therapy: opportunities and challenges, Dis Model Mech. avr, vol.8, issue.4, pp.337-50, 2015.

D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed et al., Current concepts in the diagnosis and management of cytokine release syndrome, Blood. 10 juill, vol.124, issue.2, pp.188-95, 2014.

T. T. Hansel, H. Kropshofer, T. Singer, J. A. Mitchell, and A. George, The safety and side effects of monoclonal antibodies, Nat Rev Drug Discov. avr, vol.9, issue.4, pp.325-363, 2010.

M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park et al., Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia, Sci Transl Med. 19 févr, vol.6, issue.224, pp.224-249, 2014.

D. L. Porter, W. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw et al., Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med. 2 sept, vol.7, issue.303, pp.303-139, 2015.

J. N. Brudno and J. N. Kochenderfer, Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 30 juin, vol.127, pp.3321-3351, 2016.

S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett et al., Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, N Engl J Med, vol.371, issue.16, pp.1507-1524, 2014.

E. Yescarta, EPAR -public assessment report.pdf [Internet], 2018.

E. Kymriah, EPAR -public assessment report.pdf [Internet], 2018.

, The EBMT Patient Registry

D. Sur,

. Ebmt-registry, MACRO Database Training

D. Sur,

, Lymphome | The Lymphoma Study Association

. Lysa-lymphoma,

, Arrêté du 30 avril 2019 subordonnant la prise en charge d'un médicament par l'assurance maladie au recueil et à la transmission de certaines informations relatives à sa prescription

, Missions et domaines d'intervention -Qui sommes nous ?

D. Sur,

M. Dahan, L'autorisation d'utilisation de cellules CAR T par les centres français, 2019.

, Arrêté du 28 mars 2019 limitant l'utilisation de médicament de thérapie innovante à base de lymphocytes T génétiquement modifiés dits CAR-T Cells autologues indiqués dans le traitement de la leucémie aiguë lymphoblastique à cellules B et/ou du lymphome à grande cellule B, à certains établissements de santé en application des dispositions de l'article L. 1151-1 du code de la santé publique

N. Milpied, Le CAR T dans la pratique clinique : mise en place du parcours patient. Adera meeting, 2019.

, Code de la santé publique -Article L5126-5. Code de la santé publique

, Autorisations d'activités portant sur les médicaments de thérapie innovante préparés ponctuellement (MTI PP) -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Breilh, Le rôle du pharmacien dans la mise en place des thérapies par CAR T à l'hôpital, 2019.

I. Yakoub-agha, C. Ferrand, Y. Chalandon, C. Ballot, C. Llorente et al., Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l'antigène (CAR T-cells) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bull Cancer, vol.104, issue.12, pp.43-58, 2017.

, Arrêté du 14 septembre 2009 fixant le contenu du dossier accompagnant la demande d'autorisation ou la demande de renouvellement d'autorisation d'effectuer des prélèvements de cellules à des fins thérapeutiques

, des dossiers de demandes d'autorisation ou de renouvellement d'autorisation des activités relatives aux tissus, à leurs dérivés, aux cellules et aux préparations de thérapie cellulaire

, Notice technique PMSI 2019 | Publication ATIH

D. Sur,

, 27Z024 Allogreffes de cellules souches hématopoïétiques

, Haute Autorité de Santé -Avis n° 2019.0011/AC/SEAP du 27 février 2019 du collège de la HAS relatif à l'inscription sur la LAP mentionnée à l'article L. 162-1-7 du CSS, des actes associés au traitement par CAR-T Cells

, ATIH. Notice technique ATIH. Les nouveautes du financement 2019

D. Sur,

, 17M084 Leucémies aigües, âge inférieur à 18 ans, niveau 4 -Code GHM

, 17M154 Lymphomes et autres affections malignes... -Code GHM

I. Maachi, Circuit pharmaceutique des CAR T cells au CHU de Bordeaux. Adera meeting; 2019 mars 13

J. Gauthier, Traitement par cellules CAR-T : état des lieux de leur utilisation aux États-Unis en, Bull Cancer (Paris). 1 déc, vol.105, pp.214-221, 2018.

, Risk Evaluation and Mitigation Strategies (REMS)

D. Sur,

Y. , Risk Evaluation and Mitigation Strategy (REMS

. Standards and . Resources,

J. Gauthier, Dear Tweeps, I've been asked to review the current #CARTcell panorama in the US. If you are a hem/onc/BMT physician practicing in the US I would appreciate your insight: If you consider a patient for CD19 CAR-T cell tx would you favor (assuming insurance clearance): [Internet]. @drjgauthier. 2018T14:30

, CAR-T Cell Therapy Program -Department home

, Mayo Clinic

D. Sur,